KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Asset Writedowns and Impairment (2017 - 2026)

Amneal Pharmaceuticals has reported Asset Writedowns and Impairment over the past 9 years, most recently at $26.6 million for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $26.6 million; the TTM value through Dec 2025 reached $49.4 million, up 5273.48%, while the annual FY2025 figure was $86.0 million, 9243.7% up from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 was $26.6 million at Amneal Pharmaceuticals, up from $22.8 million in the prior quarter.
  • Over five years, Asset Writedowns and Impairment peaked at $45.3 million in Q4 2022 and troughed at -$40.6 million in Q3 2024.
  • A 5-year average of $12.5 million and a median of $15.4 million in 2021 define the central range for Asset Writedowns and Impairment.
  • Biggest five-year swings in Asset Writedowns and Impairment: surged 2625.29% in 2023 and later tumbled 373.57% in 2024.
  • Year by year, Asset Writedowns and Impairment stood at $22.0 million in 2021, then skyrocketed by 105.94% to $45.3 million in 2022, then tumbled by 60.17% to $18.0 million in 2023, then tumbled by 324.79% to -$40.6 million in 2024, then skyrocketed by 165.65% to $26.6 million in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for AMRX at $26.6 million in Q4 2025, $22.8 million in Q3 2025, and -$40.6 million in Q3 2024.